# Feasibility Study of HIF2A Inhibitor PT2385 to Treat Muscle Strain Injury

> **NIH NIH R41** · HAWA THERAPEUTICS LLC · 2020 · $245,050

## Abstract

ABSTRACT Multi-PIs: Yin, A (HAWA Therapeutics) and Yin, H (UGA)
Muscle strain injury (also called pulled muscle or eccentric contraction-induced muscle injury) is a common health
problem affecting everyone in daily life. A mildly strained muscle may recover completely within one to two
weeks; whereas moderate-to-severe muscle strains usually result in a prolonged and incomplete recovery with
persistent pain, myofiber atrophy, and fibrotic scar formation in the injured muscles. Although muscle strains are
common, our current knowledge of the healing process and therapeutic approaches are very limited and
ineffective. Our promising preliminary data demonstrate that a small-molecule inhibitor of hypoxia-inducible
factor 2 alpha (HIF2A) can significantly improve the muscle regeneration and functional recovery after
moderate/severe muscle strains in animal models. These data support therapeutic applications of HIF2A inhibitor
for treating moderate-to-severe muscle strains. The ultimate goal of HAWA Therapeutics is to commercialize
topical and muscle injection formulations of HIF2A inhibitors for treating muscle strains. The objectives of the
proposed Phase I STTR study are to: 1) test the feasibility and efficacy of HIF2A inhibitor PT2385, and 2)
determine the effectiveness and toxicity of PT2385 in vitro and in vivo. The successful accomplishment of this
proposed study will pave the way for pre- and clinical trials of HIF2A inhibitor treatments in large animals and
human patients. If this product is proved to be efficacious and safe, the commercialization of the product will
benefit millions of people in the future.

## Key facts

- **NIH application ID:** 10008375
- **Project number:** 1R41OD030519-01
- **Recipient organization:** HAWA THERAPEUTICS LLC
- **Principal Investigator:** Amelia Yin
- **Activity code:** R41 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $245,050
- **Award type:** 1
- **Project period:** 2020-09-01 → 2022-08-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10008375

## Citation

> US National Institutes of Health, RePORTER application 10008375, Feasibility Study of HIF2A Inhibitor PT2385 to Treat Muscle Strain Injury (1R41OD030519-01). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10008375. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*